Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation

Keyphrases

• Inflammation 100%
• Proof of Concept Study 100%
• Cardiac Injury 100%
• COVID-19 100%
• Canakinumab 100%
• Time to Clinical Improvement 30%
• Placebo 20%
• Myocardial Injury 20%
• Confidence Interval 20%
• Day 14 20%
• Recovery Rate 20%
• Rate Ratio 20%
• Monoclonal Antibody 10%
• Hospitalization 10%
• Systemic Inflammation 10%
• Interleukin-1β 10%
• High Mortality 10%
• High Dose 10%
• Adverse Events 10%
• C-reactive Protein 10%
• Safety Concerns 10%
• Efficacy Outcomes 10%
• Placebo Groups 10%
• Between-group 10%
• Ordinal Scale 10%
• Two-point 10%
• Protein Concentration 10%
• Treatment-related Mortality 10%
• Death Events 10%
• Elevated Troponin 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Heart Injury 100%
• Coronavirinae 100%
• Inflammation 100%
• Canakinumab 100%
• Diseases 100%
• Placebo 30%
• Heart Muscle Injury 20%
• Cytokine 10%
• Adverse Event 10%
• C Reactive Protein 10%
• Monoclonal Antibody 10%
• Troponin 10%